Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation
- 18 January 2025
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 184.e1-184.e11
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Takeda Pharmaceutical Company
This publication has 40 references indexed in Scilit:
- Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infectionAnnals of Hematology, 2023
- Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United StatesPharmacoEconomics - Open, 2023
- Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2020
- Clinical and economic impact of treated CMV infection in adult CMV‐seropositive patients after allogeneic hematopoietic cell transplantationJournal of Medical Virology, 2020
- Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive StrategyTransplantation and Cellular Therapy, 2019
- Clinical and Economic Impact of Cytomegalovirus Infection among Children Undergoing Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2019
- Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological statusClinical Microbiology and Infection, 2016
- Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2009
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood levelAmerican Journal of Hematology, 2007